Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
35 hedge funds and large institutions have $72.8M invested in Biora Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 18 closing their positions.
282% more call options, than puts
Call options by funds: $6.11M | Put options by funds: $1.6M
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 42 → 35 (-7)
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
63% less capital invested
Capital invested by funds: $196M → $72.8M (-$124M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.4M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.16M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.05M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$210K |
| 5 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$27.1M |
| 2 |
PGM
Parian Global Management
Pound Ridge,
New York
|
-$4.77M |
| 3 |
D.E. Shaw & Co
New York
|
-$864K |
| 4 |
RI
RTW Investments
New York
|
-$357K |
| 5 |
E
Ergoteles
New York
|
-$292K |
BIOR Hedge Fund Activity: Q3 2021 in Review
35 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q3 2021, worth a combined $72.8M — down 63% from $196M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of BIOR and 11 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 11 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.4M. The largest seller was Armistice Capital, exiting entirely with an estimated $27.1M sold.
- 35 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q3 2021, down from 42 in Q2 2021.
- Funds reported $72.8M of Biora Therapeutics, Inc. Common Stock stock for Q3 2021, down 63% quarter-over-quarter.
- 11 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q3 2021 and 18 closed out, a net change of -7 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q3 2021 was Renaissance Technologies, an estimated $1.4M added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q3 2021 was Armistice Capital, an estimated $27.1M sold.
Based on aggregated 13F filings for Q3 2021.